Management of orbital invasion in sinonasal squamous cell carcinoma: 15 years' experience

Int Forum Allergy Rhinol. 2020 Feb;10(2):243-255. doi: 10.1002/alr.22465. Epub 2019 Nov 22.

Abstract

Background: This study was intended to review our management strategy for sinonasal squamous cell carcinomas (SNSCCs) with orbital invasion and to explore the role of radiotherapy in orbital preservation.

Methods: We retrospectively analyzed 93 SNSCC patients with orbital invasion who underwent radiotherapy with or without surgery over the past 15 years. The degree of orbital invasion was classified into 3 grades.

Results: Eighty-eight patients presented with T4 tumors and 36 had grade III orbital invasion. Seventy-two patients received surgery plus radiation and 67 received platinum-based chemotherapy. The median follow-up for surviving patients was 60 months. Five-year overall survival (OS) for the whole group was 57.4%. The patients treated with surgery plus radiation had a 5-year survival rate of 62.2% and orbital preservation was feasible in 90.3% of cases. Twenty-one patients with SNSCCs that extended into the extraocular muscles or eye globe also underwent orbital preservation. Five-year locoregional relapse-free survival (LRFS) was 69.5% for patients treated with orbital preservation and 57.1% for those treated with orbital exenteration, indicating no statistical difference. Five-year survival, 5-year progression-free survival (PFS), and 5-year distant metastasis-free survival (DMFS) were similar between groups. Grade III orbital invasion was independently associated with shorter OS, LRFS, PFS, and DMFS.

Conclusion: Orbital invasion in grade III was associated with the worst survival outcomes. Invasion of either the extraocular muscles or eye globe is not a contraindication for eye-sparing surgery. Preoperative chemoradiation continues to offer hope to patients with a strong desire to preserve their eyes.

Keywords: head and neck cancer; orbital invasion; orbital preservation; prognostic factors; radiotherapy; sinonasal squamous cell carcinomas.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Squamous Cell* / drug therapy
  • Carcinoma, Squamous Cell* / radiotherapy
  • Carcinoma, Squamous Cell* / secondary
  • Carcinoma, Squamous Cell* / surgery
  • Cisplatin / therapeutic use
  • Combined Modality Therapy
  • Female
  • Fluorouracil / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Orbital Neoplasms* / drug therapy
  • Orbital Neoplasms* / pathology
  • Orbital Neoplasms* / radiotherapy
  • Orbital Neoplasms* / surgery
  • Paranasal Sinus Neoplasms* / drug therapy
  • Paranasal Sinus Neoplasms* / pathology
  • Paranasal Sinus Neoplasms* / radiotherapy
  • Paranasal Sinus Neoplasms* / surgery
  • Survival Analysis

Substances

  • Antineoplastic Agents
  • Cisplatin
  • Fluorouracil